Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 2:37 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 961–984 of 2,391 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pancreatic Cancer Clear all
Completed Phase 3 Interventional Results available

Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions

NCT01936467
View directory record Official record
Conditions
Pancreatic Solid Lesions, Pancreatic Mass
Interventions
Standard technique EUS-FNA, Capillary suction technique for EUS FNA
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Nov 2, 2026, 2:37 AM EST
Recruiting No phase listed Observational

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

NCT01416714
View directory record Official record
Conditions
Gastric Cancers
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 2, 2026, 2:37 AM EST
Completed Phase 1 Interventional

LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

NCT01485744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 72 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Nov 2, 2026, 2:37 AM EST
Withdrawn Not applicable Interventional

Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures

NCT02366858
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
19 gauge, 22 gauge
Procedure
Lead sponsor
AdventHealth
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Nov 2, 2026, 2:37 AM EST
Not listed No phase listed Observational

Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study

NCT05051358
View directory record Official record
Conditions
Therapeutic Endoscopic Ultrasound, Advanced Endoscopy, Therapeutic Endoscopy, Interventional Endoscopy, Interventional Endoscopic Ultrasound, Gastro-Intestinal Disorder, Gastrointestinal Disease, Gastrointestinal Cancer, Gastrointestinal Dysfunction, Gastrointestinal Fistula, Gastrointestinal Infection, Gastrointestinal Injury, Pancreatic Disease, Bile Duct Diseases
Interventions
Therapeutic Endoscopic Ultrasound
Procedure
Lead sponsor
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Nov 2, 2026, 2:37 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

NCT06907043
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
EIK1004-001 (IMP1707-001)
Drug
Lead sponsor
Eikon Therapeutics
Industry
Eligibility
18 Years to 89 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Denver, Colorado • Lake Mary, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Nov 2, 2026, 2:37 AM EST
Completed Phase 1Phase 2 Interventional

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

NCT03953235
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor, Shared Neoantigen-Positive Solid Tumors
Interventions
GRT-C903, GRT-R904, nivolumab, ipilimumab
Biological
Lead sponsor
Gritstone bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
12
States / cities
Phoenix, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Nov 2, 2026, 2:37 AM EST
Completed Not applicable Interventional Results available

Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients

NCT02245217
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
PET/CT scan to assess treatment efficacy
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Nov 2, 2026, 2:37 AM EST
Terminated No phase listed Observational

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

NCT02900248
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Nov 2, 2026, 2:37 AM EST
Enrolling by invitation Not applicable Interventional

Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms

NCT07619417
View directory record Official record
Conditions
Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor
Interventions
Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas, PEF-ablation of pancreatic cyst
Other · Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Terminated Phase 1Phase 2 Interventional Results available

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

NCT03745326
View directory record Official record
Conditions
Gastrointestinal Cancer, Pancreatic Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer
Interventions
Cyclophosphamide, Fludarabine, Aldesleukin, anti-Kirsten rat sarcoma virus (KRAS) Glycine(G) to Aspartic Acid(D) substitution at codon 12 peripheral blood lymphocytes (PBL), EKG, CT, MRI, PET, Chest x-ray, Photography
Drug · Biological · Diagnostic Test + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Terminated Phase 2 Interventional Results available

Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma

NCT03469258
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Pancrelipase
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Nov 2, 2026, 2:37 AM EST
Completed No phase listed Observational

B-Receptor Signaling in Cardiomyopathy

NCT01135849
View directory record Official record
Conditions
Carcinomas, Amyloidosis, Anal Cancer, Anemia, Cholangiocarcinoma of the Extrahepatic Bile Duct, Transitional Cell Carcinoma of Bladder, Bone Marrow Transplant Failure, Bone Cancer, Cancer of Brain and Nervous System, Breast Cancer, Carcinoma of the Large Intestine, Endocrine Cancer, Esophageal Cancer, Eye Cancer, Gall Bladder Cancer, Gastric (Stomach) Cancer, Gastrooesophageal Cancer, Gastrointestinal Stromal Tumor (GIST), Gynecologic Cancers, Head and Neck Cancers, Hepatobiliary Neoplasm, Kidney (Renal Cell) Cancer, Leukemia, Lung Cancer, Hodgkin Disease, Lymphoma, Non-Hodgkin, Mesothelioma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Neuroendocrine Tumors, Myeloproliferative Disorders, Pancreatic Cancer, Prostate Cancer, Skin Cancer, Soft Tissue Sarcoma, Testicular Cancer, Thymus Cancer, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Daniel Bernstein
Other
Eligibility
Up to 40 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Nov 2, 2026, 2:37 AM EST
Terminated Phase 2 Interventional Results available

Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

NCT03723915
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pembrolizumab, Wild-type Reovirus
Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Nov 2, 2026, 2:37 AM EST
Completed No phase listed Observational

Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients

NCT02400398
View directory record Official record
Conditions
Pancreatic Neoplasms, Pancreatic Cancer, Cachexia, Weight Loss
Interventions
Tube feeding
Other
Lead sponsor
Andrew Hendifar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Nov 2, 2026, 2:37 AM EST
Recruiting Phase 2Phase 3 Interventional

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

NCT06943755
View directory record Official record
Conditions
Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
Interventions
Zanzalintinib, Everolimus
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Active, not recruiting Phase 1 Interventional

P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors

NCT05239143
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Renal Cell Carcinoma, Nasopharyngeal Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer
Interventions
P-MUC1C-ALLO1 CAR-T cells, Rimiducid
Biological · Drug
Lead sponsor
Poseida Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2039
U.S. locations
14
States / cities
Irvine, California • Los Angeles, California • San Diego, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04477343
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer
Interventions
SX-682, Nivolumab Injectable Product
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Terminated Phase 2 Interventional Results available

Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer

NCT00470535
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Nov 2, 2026, 2:37 AM EST
Terminated Phase 2 Interventional Results available

Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery

NCT02315625
View directory record Official record
Conditions
Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas
Interventions
Sunitinib, Everolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Nov 2, 2026, 2:37 AM EST
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer

NCT02454140
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
SBRT
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 2, 2026, 2:37 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

NCT07224750
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Esophageal Squamous Cell Carcinoma (ESCC), Gastric Cancer (GC), Colorectal Cancer Screening
Interventions
Not listed
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Recruiting Phase 1 Interventional

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

NCT06451497
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Pancreas Adenocarcinoma, Biliary Tract Cancer, Prostate Cancer, Urothelial Carcinoma, Colorectal Cancer, Triple Negative Breast Cancer, High Grade Ovarian Serous Adenocarcinoma, Diffuse Large B Cell Lymphoma, Renal Cell Cancer Metastatic
Interventions
ZM008
Biological
Lead sponsor
Zumutor Biologics Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Austin, TX 78758, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Nov 2, 2026, 2:37 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC

NCT04605913
View directory record Official record
Conditions
Pancreas Cancer, Metastatic Pancreatic Cancer, Pancreatic Adenocarcinoma, Metastatic Adenocarcinoma
Interventions
Modified GCN+TTF treatment
Combination Product
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 2, 2026, 2:37 AM EST